Leridistim

From WikiMD's WELLNESSPEDIA

Leridistim




Synonyms SC-70935











Identifiers
CAS Number 193574-27-3















Leridistim is a recombinant protein that acts as a dual cytokine receptor agonist, specifically targeting both the granulocyte colony-stimulating factor (G-CSF) and interleukin-3 (IL-3) receptors. It is primarily investigated for its potential to stimulate the production of white blood cells, particularly in patients undergoing chemotherapy who are at risk of neutropenia.

Mechanism of Action[edit]

Leridistim functions by binding to and activating the G-CSF and IL-3 receptors on hematopoietic progenitor cells. This dual receptor activation leads to the proliferation and differentiation of these progenitor cells into mature granulocytes and other myeloid cells. The stimulation of these pathways enhances the body's ability to produce white blood cells, thereby reducing the duration and severity of neutropenia in patients receiving myelosuppressive chemotherapy.

Clinical Development[edit]

Leridistim has been evaluated in several clinical trials to assess its efficacy and safety in reducing chemotherapy-induced neutropenia. Early-phase studies demonstrated its potential to increase white blood cell counts more effectively than G-CSF alone. However, further development was halted due to concerns about adverse effects and the emergence of other therapeutic agents with more favorable profiles.

Adverse Effects[edit]

The administration of Leridistim has been associated with several side effects, including bone pain, fatigue, and injection site reactions. More serious adverse effects, such as splenomegaly and thrombocytopenia, have also been reported, which contributed to the discontinuation of its development.

Current Status[edit]

As of the latest updates, Leridistim is not approved for clinical use and remains an investigational drug. Research into similar dual receptor agonists continues, with the aim of finding safer and more effective treatments for neutropenia.

Also see[edit]


Receptor agonists
Adrenergic
Dopaminergic
Serotonergic
Histaminergic
GABAergic

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Leridistim&oldid=6025140"